RE:RE:RE:RE:RE:RE:RE:Down it goesSo here's what I find frustrating.. every time I try to genuinly understand your position and generate concrete discussion with specifics you just reply with more generalities ..
So let's try this again. As an example, if WEED (~30x '20 EBITDA) or ACB (22x '20 EBITDA) or even LEAF (~12x EBITDA) bought THCX (~6x '20 EBITDA) it would be highly accretive to the buyer. Higher multiple buyer, lower multiple target = accretive. Add on top of that the strategic rationale of low labor/power in Quebec + a market controling supply deal and you quickly begin to see where the upside for THCX comes from BEFORE rec goes live.
RE: history of M&A comment (which btw adds zero value this conversation when you say it on its own): Do I think ACB overpaid for Cannimed, absolutly, but that is not the case with or relevant in realtion to THCX (see multiples above). And seeing that ACB and LEAF are in real tangible discussions, there is clearly appetite for M&A out there which would be silly for you to ignore.
Rothchildish wrote: Look at the history of acquisitions / mergers, I don't need to elaborate more on this subject, it speaks for itself. Hey THCX should buy MYM for 1B, since they will have 2M sq feet!!!!